Skip to main content

Table 1 Patient characteristics before and after dexamethasone 4 mg/day for 4 days

From: Evidence for transcript-specific epigenetic regulation of glucocorticoid-stimulated skeletal muscle 11β-hydroxysteroid dehydrogenase-1 activity in type 2 diabetes

Characteristic

Pre dexamethasone

Post dexamethasone

Fasting glucose (mmol/l)

7.0 (6.1 to 9.8)

7.6 (6.4 to 12.9)a

Fasting insulin (mU/l)

13.1 (9.6 to 15.5)

15.8 (11.4 to 17.8)a

HOMA2-IR

2.0 (1.3 to 2.1)

2.4 (1.6 to 2.9)b

11βHSD1 mRNA (relative expression)

3.06 (1.81 to 4.61)

3.06 (2.70 to 6.11)b

11βHSD1 oxoreductase activity (% conversion)

11.3 (4.7 to 17.4)

15.5 (11.6 to 19.3)a

C/EBPβ mRNA (relative expression)

1.37 (0.32 to 2.46)

2.06 (0.85 to 3.11) a

P1 promoter mRNA (relative expression, n = 11)

0.03 (0.02 to 0.04)

0.06 (0.03 to 0.22)b

P2 promoter mRNA (relative expression, n = 11)

0.83 (0.63 to 1.13)

1.40 (0.77 to 1.78)a

  1. Data presented as median (25th to 75th percentile). The Wilcoxon signed-rank test examined the significance of the median difference between paired values. 11βHSD1, 11β-hydroxysteroid dehydrogenase-1; C/EBP, CCAAT/enhancer-binding protein; HOMA, homeostasis model assessment. P <0.05 compared with pre dexamethasonea. P < 0.01compared with pre dexamethasoneb.